Skip to content
Screener

Amphastar Pharmaceuticals AMPH Total Current Liabilities

Total Current Liabilities at other companies

Pfizer logo
PfizerPFE
$34.35B-5.8%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$344.44M+157%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$122.8M-3.4%
Viatris logo
ViatrisVTRS
$6.35B-11.0%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$31.75M+73.5%
Opko Health logo
Opko HealthOPK
$149.37M-12.7%

Other financials

Income statement

See full
Revenue$183.9M+5.4%
Gross profit$93.5M+8.1%
Operating income$39.7M-5.8%
Net income$30.3M-2.2%
EPS (diluted)$0.67+4.7%

Balance sheet

See full
Cash & equivalents$223.6M+19.1%
Total debt$688.5M+5.0%
Total equity$445.5M—
Total assets$1.7B+8.0%

Cash flow

See full
Operating cash flow$51.3M+44.2%
CapEx$8.6M-18.7%
Free cash flow$42.7M+70.7%

Valuation

See full
Market cap$916.25M-28.0%
Enterprise value$1.38B-20.6%
P/E11.7×+2.2×
P/S1.3×-0.5×

Profitability

See full
Gross margin47.7%-2.2pp
Operating margin15.7%-9.5pp
Net margin10.8%-7.9pp
FCF margin20.9%+5.4pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio2.4×-0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:50 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001297184-26-000047
Line itemJune 30, 2026December 31, 2025
Income taxes payable546239
Current portion of long-term debt2,4881,641
Current portion of operating lease liabilities8,8007,928
Total current liabilities263,205158,156
Long-term reserve for income tax liabilities5,9265,926
Long-term debt, net of current portion and unamortized debt issuance costs609,564608,749
Long-term operating lease liabilities, net of current portion67,47037,684
Other long-term liabilities29,44429,979

Item 1. Financial Statements (unaudited)

FAQ

What is Amphastar Pharmaceuticals's total current liabilities?
Amphastar Pharmaceuticals (AMPH) reported total current liabilities of $263.21M in Q2 2026.
How has Amphastar Pharmaceuticals's total current liabilities changed year-over-year?
Amphastar Pharmaceuticals's total current liabilities increased by 49.2% year-over-year, from $176.41M to $263.21M.
What is the long-term trend for Amphastar Pharmaceuticals's total current liabilities?
Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's total current liabilities has grown at a 7.1% compound annual growth rate (CAGR), from $112.2M to $158.16M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about Amphastar Pharmaceuticals's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude